Adial Pharmaceuticals, Inc.
ADIL
$0.2454
$0.00642.68%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 5.18M | 5.06M | 5.36M | 5.34M | 5.11M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 8.71M | 8.28M | 8.13M | 7.27M | 6.46M |
Operating Income | -8.71M | -8.28M | -8.13M | -7.27M | -6.46M |
Income Before Tax | -8.95M | -13.20M | -13.03M | -12.19M | -11.24M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -8.95 | -13.20 | -13.03 | -12.19 | -11.24 |
Earnings from Discontinued Operations | -- | -- | -15.90K | -53.20K | 2.54M |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -8.95M | -13.20M | -13.05M | -12.24M | -8.69M |
EBIT | -8.71M | -8.28M | -8.13M | -7.27M | -6.46M |
EBITDA | -8.71M | -8.28M | -8.13M | -7.27M | -6.46M |
EPS Basic | -1.63 | -3.48 | -3.98 | -4.78 | -3.23 |
Normalized Basic EPS | -1.49 | -2.65 | -2.48 | -2.96 | -3.43 |
EPS Diluted | -1.63 | -3.48 | -3.98 | -4.78 | -3.23 |
Normalized Diluted EPS | -1.49 | -2.65 | -2.48 | -2.96 | -3.43 |
Average Basic Shares Outstanding | 22.97M | 19.39M | 15.31M | 10.65M | 7.60M |
Average Diluted Shares Outstanding | 22.97M | 19.39M | 15.31M | 10.65M | 7.60M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |